Sandoz Chief Warns of 'Fragile' European Antibiotic Supply Due to Cheap Chinese Imports

Sandoz CEO Richard Saynor has issued a formal warning regarding the long-term stability of Europe's antibiotic supply, citing the unsustainable reliance on low-cost Chinese imports. The report highlights how European healthcare procurement policies, which prioritize the lowest price, are systematically pushing domestic manufacturers out of the market. This competitive disadvantage leaves the continent vulnerable to severe supply chain disruptions and geopolitical volatility. Industry experts are now calling for a fundamental restructuring of public medicine tenders to favor security and regional resilience over immediate cost savings. The article explores the economic paradox of these supply chains, the inherent risks to public health infrastructure, and the necessity of achieving 'strategic autonomy' in pharmaceutical production. As policymakers weigh the costs of subsidizing or incentivizing local manufacturing against the dangers of total dependence on distant suppliers, the debate over the true value of life-critical medication remains a defining issue for European economic and social stability.